Health

InnoCare Releases 2021 Annual Results and Business Highlights

BEIJING, March 22, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2021 annual results as of31 December 2021. Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said, "We are delighted ...

2022-03-23 08:08 3035

VivaVision Biotech Announces Positive Topline Results of VVN001 in the Phase 2 Clinical Study for the Treatment of Dry Eye Disease

SHANGHAI, March 22, 2022 /PRNewswire/ -- VivaVision Biotech, Inc. (VivaVision), an ophthalmic pharmaceutical developer focusing on discovery and development of innovative therapies for ocular diseases, today announced positive topline results from a Phase 2 clinical study of VVN001 in patients wi...

2022-03-23 08:00 1714

Fosun Pharma 2021 Annual Results Announcement: Accelerating the Globalization Comprehensively

The Proportion of Revenue from Innovative Products Continues to Increase Highlights: * Revenue for the year ended December 31, 2021 was RMB39,005 million, representing an increase of 28.70% YOY; * The proportion of revenue from new products as well as regions outside Mainland China and count...

2022-03-23 06:53 3182

WuXi Biologics Achieved Record Growth and Profitability in 2021

Banner Year for Commercial Manufacturing Revenue Increased by 83.3% Y-o-Y to RMB10,290.1 Million Gross Profit Increased by 90.6% Y-o-Y to RMB4,828.9 Million Net Profit Grew by 107.3% Y-o-Y to RMB3,508.6 Million Adjusted Net Profit Rose by 100.3% to RMB3,435.9 Million Total Backlog Grew 20.1% to ...

2022-03-23 00:38 2839

INDICAID COVID-19 Rapid Antigen At-Home Test Receives FDA Emergency Use Authorization (EUA) for Over-the-Counter (OTC), Asymptomatic, Non- Prescription Use

GARDEN GROVE, Calif., March 22, 2022 /PRNewswire/ -- PHASE Scientific International, LTD  (PHASE Scientific), a high-growth biotech company founded by bioengineers fromUCLA, announces that its INDICAID® COVID-19 Rapid Antigen At-Home Test (INDICAID® OTC) recei...

2022-03-23 00:00 1882

Jacobio Announces Annual Results of 2021, R&D Investment Increases 83%

BEIJING and SHANGHAI and BOSTON, March 22, 2022 /PRNewswire/ -- Jacobio Announced its 2021 annual results on 22 March. As a clinical-stage biotech company, Jacobio's revenue wasRMB152 million, which was generated from an out-licensing deal. Its R&D investment wasRMB421 million, showing an increas...

2022-03-22 22:50 2256

IFF to Showcase Renewable Industrial Solutions and Polymer Portfolio at American Coatings Show

WILMINGTON, Del., March 22, 2022 /PRNewswire/ -- IFF's Industrial Solutions will bring its deep technical expertise, commitment to quality and broad portfolio of renewable polymers to theAmerican Coatings Show (ACS) for the first time on April 5-7.

2022-03-22 21:00 1855

NIBIOHN Identifies Tissue-specific Exosome Marker Candidates from Blood

OSAKA, Japan, March 22, 2022 /PRNewswire/ -- The National Institutes of Biomedical Innovation, Health and Nutrition (hereinafter NIBIOHN) based in Ibaraki-shi, Osaka Prefecture, has successfully catalogued more than 4,000 proteins contained in exosomes in healthy human blood (serum and plasma). Us...

2022-03-22 14:00 1344

OBiO Technology Goes Public on Shanghai Stock Exchange Today

SHANGHAI, March 22, 2022 /PRNewswire/ -- On March 22, 2022, OBiO Technology ( Shanghai) Corp., Ltd. ("OBiO" or "the Company"), has completed its initial public offering ("IPO") process and started trading on the Shanghai Stock Exchange's Sci-Tech innovation board (SSE, code: 688238). Founded in 2...

2022-03-22 13:00 2473

INTERVAPOR®, THERMAL VAPOR TREATMENT SYSTEM, APPROVED FOR MARKETING IN CHINA

HANGZHOU, China, March 21, 2022 /PRNewswire/ -- Broncus(02216HK) today is pleased to announce that InterVapor® (including InterVapor Generator and InterVapor Catheter, the "InterVapor®"), the Company's thermal vapor treatment system, has been granted approval by the National Medical Products Adm...

2022-03-22 10:34 1636

Ascentage Pharma's MDM2-p53 Inhibitor Alrizomadlin (APG-115) Granted Rare Pediatric Disease Designation by the US FDA for the Treatment of Neuroblastoma

SUZHOU, China, and ROCKVILLE, MD, March 21, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its novel MDM2-p53 inhibitor, alrizomadlin ...

2022-03-22 09:15 1617

Transnetyx Announces Acquisition of a-tune

MEMPHIS, Tenn., March 22, 2022 /PRNewswire/ -- Transnetyx, a global leader in outsourced genetic services, announced the acquisition of a-tune, a best-in-class software for animal research and compliance. This acquisition allows Transnetyx to partner with a-tune to further streamline animal resea...

2022-03-22 04:30 2076

Cali Biosciences Announces Successful Results in Phase IIb Study of Long-Acting Ropivacaine (CPL-01) for Non-Opioid Treatment of Post-Operative Pain

SAN DIEGO, March 21, 2022 /PRNewswire/ -- Cali Biosciences Co., Ltd. (hereinafter referred to as "Cali Biosciences"), a biopharmaceutical company focused on the research and development of innovative drugs, announced successful results in its Phase IIb study of its perioperative long-acting anal...

2022-03-22 00:00 1752

Ascentage Pharma Announces 2021 Annual Results with Commercialization Programs Going Full Steam Ahead

SUZHOU, China and ROCKVILLE, Md., March. 21, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today released its annual results for full year 2021, during whi...

2022-03-21 23:11 2657

BIOKANGTAI Signs a Cooperation Agreement with the Largest Importer of Parenteral Products in Philippines

SHENZHEN, China, March 21, 2022 /PRNewswire/ -- On March 17, 2022, Shenzhen Kangtai Biological Products Co., Ltd signed a framework agreement with Phil.PharmaWealth Inc., the largest importer of Parenteral Products in Philippines, and both parties reached an agreement on jointly promoting the reg...

2022-03-21 22:22 1925

3billion to reveal its diagnostic performance at ACMG annual meeting 2022

SEOUL, South Korea, March 21, 2022 /PRNewswire/ -- 3billion announced that Chief Medical Officer Dr.Go Hun Seo will introduce a research poster at ACMG annual meeting 2022, held inNashville, TN, from March 22 through 26. This poster highlights the importance of continuous reanalysis for undiagnos...

2022-03-21 22:00 1759

ABclonal Technology Joins YCharOS Industry Advisory Committee to Tackle Reproducibility Crisis in Biomedical Research

BOSTON, March 21, 2022 /PRNewswire/ -- ABclonal Technology, a rapidly growing life science research and diagnostic reagents manufacturer, today announced it has joined the Industry Advisory Committee (IAC) at YCharOS Inc., an open science company with the mission of characterizing commercially av...

2022-03-21 20:15 1899

KAZIA TO PRESENT AT UPCOMING INVESTOR CONFERENCE AND AACR ANNUAL SCIENTIFIC MEETING

SYDNEY, March 21, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late stage, oncology-focused drug development company, is pleased to announce upcoming presentations at two international conferences. American Association of Cancer Research Annual Scientific Meeting ...

2022-03-21 20:00 2543

RNAGENE Signs a Collaborative Research Agreement with PharmAbcine to Develop Novel mRNA Therapeutics

SEOUL, South Korea, March 21, 2022 /PRNewswire/ -- RNAGene Inc., a South Korean biotech which specializes in the development of mRNA (messenger ribonucleic acid)-based therapeutics, announced today that it has signed a Collaborative Research Agreement with PharmAbcine Inc. (KOSDAQ: 208340ks), a c...

2022-03-21 20:00 1687

Nuance Pharma Announces License and Supply Agreement with Bavarian Nordic on the Development and Commercialization of Respiratory Syncytial Virus (RSV) Vaccine for Adults in China and Selected Asian Markets

* Bavarian Nordic to receive up to USD 225 million in upfront and milestone payments in addition to tiered, double-digit royalties * Nuance Pharma obtains rights to commercialize MVA-BN® RSV in Chinese Mainland,Hong Kong, Macau, Taiwan, South Korea and Southeast Asia and will be responsible f...

2022-03-21 16:20 1618
1 ... 166167168169170171172 ... 279